Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mycobacterium tuberculosis Heat Shock Protein 70 (TBHSP70) is a 70 kDa molecular chaperone that is essential for protein homeostasis and stress survival within the tuberculosis bacterium. In the context of vaccinology, TBHSP70 is recognized as a potent immune adjuvant due to its ability to bridge innate and adaptive immunity. It functions by engaging pattern recognition receptors, specifically Toll-like receptors 2 and 4 (TLR2/4), on the surface of dendritic cells and macrophages, which triggers cellular maturation and the production of Th1-polarizing cytokines (Zugel and Kaufmann, 1999, Immunobiology). Beyond its role as a TLR agonist, TBHSP70 acts as a carrier for antigens, facilitating their uptake via receptors like CD91 and CD40. This process allows for the efficient cross-presentation of chaperoned peptides on MHC class I molecules, leading to the activation of cytotoxic T-lymphocytes (CTLs), which are critical for eliminating intracellular pathogens and tumor cells (Tobian et al., 2004, J Immunol). Because of these dual immunostimulatory properties, TBHSP70 is frequently utilized in the design of recombinant subunit vaccines and DNA vaccines for both infectious diseases and oncology. The input name provided is considered incorrect as it describes the biological pathways and mechanism of action rather than the specific molecule itself.
TBHSP70 acts as an adjuvant by binding to pattern recognition receptors (PRRs) such as Toll-like receptors 2 and 4 (TLR2/4) and endocytic receptors like CD91 and CD40 on antigen-presenting cells (APCs). This interaction stimulates the maturation of dendritic cells and the secretion of pro-inflammatory cytokines (e.g., IL-12, TNF-alpha). Furthermore, TBHSP70 chaperones associated antigens into the MHC class I and II pathways, facilitating cross-presentation and the induction of robust CD8+ and CD4+ T-cell responses (Bulut et al., 2005, J Immunol; Wang et al., 2001, Immunity).
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mycobacterium tuberculosis Heat Shock Protein 70 (TBHSP70).